Company
TELA Bio, Inc.
Headquarters: Malvern, PA, United States
Employees: 108
CEO: Mr. Antony Koblish
Market Cap
$105.2 Million
USD as of Jan. 1, 2025
TELA Bio, Inc. Categories
United States Healthcare Medical DevicesUnited States Healthcare United States Medical Devices
Top Competitors by Market Capitalization
Industry: Medical Devices
| Company | Market Cap (USD) |
|---|---|
| Abbott | $213.72 B |
| Stryker | $150.01 B |
| Boston Scientific Corporation | $149.80 B |
| Medtronic | $114.44 B |
| Shenzhen Mindray Bio-Medical Electronics Co. Ltd | $47.37 B |
Sector:
| Company | Market Cap (USD) |
|---|---|
| Lilly | $689.42 B |
| Novo Nordisk | $622.07 B |
| UnitedHealth Group | $487.54 B |
| Johnson & Johnson | $353.05 B |
| AbbVie | $301.60 B |
Detailed Description
TELA Bio, Inc., a medical technology company, focuses on the design, development, and marketing of tissue reinforcement materials to address unmet needs in soft tissue reconstruction. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.
Financials
| Last Financial Reports Date | Dec. 31, 2023 |
| Revenue TTM | $58.5 M |
| EBITDA | $-43,267,000 |
| Gross Profit TTM | $40.1 M |
| Profit Margin | -79.83% |
| Operating Margin | -72.23% |
| Quarterly Revenue Growth | 46.30% |
Stocks & Indices
TELA Bio, Inc. has the following listings and related stock indices.
Stock: NASDAQ: TELA wb_incandescent